Neuralstem, Inc. President and CEO Publishes New Blogadmin
Neuralstem, Inc. (NYSE MKT: CUR) published a blog post entitled “Beauty and the Beast” on the Company’s website (http://neuralstem.com/neuralstem-ceo-blog/196-both-a-little-scared-neither-one-prepared-beauty-and-the-beast) which was republished on TheChairmansBlog.com.
In his new blog, Neuralstem’s President and CEO Richard Garr writes about the changes in the life science industry he has observed in recent years. Mr. Garr highlights “big pharma’s” shift in focus towards developing therapies to treat rare diseases with smaller indications and its potential effect on smaller companies like Neuralstem.
Neuralstem’s patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed dosing of the last patient in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease, in August 2012; the trial ends six months after that last surgery. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.
TheChairmansBlog.com is an exclusive, online media publication where publically and privatively held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. In addition to management`s insightful blog posts, TheChairmansBlog.com staff and aggregate partners contribute articles on finance, technology, health, and energy while providing updated market trends, news, and information.
Posted: October 31st, 2013 under ACCESSWIRE.